Amoxapine - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for amoxapine and what is the scope of patent protection?

Amoxapine is the generic ingredient in two branded drugs marketed by Chartwell Rx, Watson Labs, Watson Pharms Teva, and Lederle, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for amoxapine. Two suppliers are listed for this compound.

Summary for amoxapine

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	7
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	4
Patent Applications:	6,585
Drug Prices:	Drug price trends for amoxapine
What excipients (inactive ingredients) are in amoxapine?	amoxapine excipients list
DailyMed Link:	amoxapine at DailyMed

See drug prices for amoxapine

Recent Clinical Trials for amoxapine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Federal University of São Paulo	Phase 4
Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4
Alexza Pharmaceuticals, Inc.	Phase 1

See all amoxapine clinical trials

Pharmacology for amoxapine

Drug Class	Tricyclic Antidepressant

Medical Subject Heading (MeSH) Categories for amoxapine

Adrenergic Uptake Inhibitors
Antidepressive Agents, Second-Generation
Dopamine Antagonists
Neurotransmitter Uptake Inhibitors
Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for amoxapine

N06AA	Non-selective monoamine reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for amoxapine

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Watson Labs	AMOXAPINE	amoxapine	TABLET;ORAL	072691-004	Aug 28, 1992		RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Chartwell Rx	AMOXAPINE	amoxapine	TABLET;ORAL	072879-002	Jun 28, 1991		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-003	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for amoxapine

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-004	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-003	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-004	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Lederle	ASENDIN	amoxapine	TABLET;ORAL	018021-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.